Market Closed - Nasdaq 04:00:00 2024-04-24 pm EDT 5-day change 1st Jan Change
23.05 USD -0.52% Intraday chart for AtriCure, Inc. -1.71% -35.42%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Oppenheimer Upgrades AtriCure to Outperform, Price Target at $32 MT
AtriCure, Inc. Announces Launch of the CryoSPHERE®?+ Probe for Post-Operative Pain Management CI
AtriCure Insider Sold Shares Worth $307,510, According to a Recent SEC Filing MT
Atricure, Inc. Appoints Shlomi Nachman as Director, Member of Each of the Board?s Strategy Committee and Compliance, Quality and Risk Committee CI
UBS Adjusts AtriCure Price Target to $58 From $57, Maintains Buy Rating MT
Stifel Adjusts Price Target on AtriCure to $42 From $50, Maintains Buy Rating MT
Needham Adjusts Price Target on AtriCure to $46 From $44, Keeps Buy Rating MT
AtriCure Q4 Loss Widens, Revenue Rises; 2024 Guidance Set MT
Transcript : AtriCure, Inc., Q4 2023 Earnings Call, Feb 15, 2024
Earnings Flash (ATRC) ATRICURE Reports Q4 Revenue $106.5M, vs. Street Est of $104.2M MT
Atricure, Inc. Provides Earnings Guidance for 2024 CI
AtriCure, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
UBS Adjusts AtriCure Price Target to $57 From $56, Maintains Buy Rating MT
Transcript : AtriCure, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 07:30 AM
AtriCure Reports Higher Preliminary Q4, 2023 Revenue; Issues 2024 Revenue Guidance; Shares Rise MT
AtriCure, Inc. and Its Wholly Owned Subsidiary, Atricure, LLC Enters into an Asset-Based Credit Agreement CI
Atricure, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year of 2023 and Provides Financial Guidance for the Year 2024 CI
AtriCure, Inc. Appoints Shlomi Nachman to its Board of Directors CI
AtriCure's Q3 Adjusted Loss Narrows, Revenue Rises; Full-Year Guidance Adjusted MT
Transcript : AtriCure, Inc., Q3 2023 Earnings Call, Nov 01, 2023
Earnings Flash (ATRC) ATRICURE Posts Q3 Revenue $98.3M, vs. Street Est of $96.6M MT
AtriCure, Inc. Provides Revenue Guidance for the 2023 CI
AtriCure, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
JMP Securities Initiates AtriCure With Market Outperform Rating, Price Target is $60 MT
UBS Initiates AtriCure With Buy Rating, Price Target is $56 MT
Chart AtriCure, Inc.
More charts
AtriCure, Inc. provides technologies for the treatment for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management. The Company's cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Its pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures. The Company's products for open and minimally invasive ablation include Isolator Synergy Clamps and Multifunctional Pens and Linear Ablation Devices. Its products for open ablation include cryoICE Cryoablation System. Its products for minimally invasive ablation include EPi-Sense Guided Coagulation System with VisiTrax Technology. Its appendage management products include AtriClip System. The Isolator Synergy Ablation System clamps are single-use disposable radio frequency (RF) products with jaws that close in a parallel fashion.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
23.05 USD
Average target price
51.89 USD
Spread / Average Target
+125.11%
Consensus
  1. Stock Market
  2. Equities
  3. ATRC Stock
  4. News AtriCure, Inc.
  5. Insider Trends: Insider Adds to Selling Trend at AtriCure